ARVN
NASDAQ · Pharmaceuticals
Arvinas Inc
$6.55
-0.87 (-11.73%)
Financial Highlights (FY 2026)
Revenue
242.17M
Net Income
-74,512,784
Gross Margin
—
Profit Margin
-30.8%
Rev Growth
+26.0%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 45.0% | 45.0% |
| Operating Margin | -45.1% | -40.6% | 18.2% | 21.8% |
| Profit Margin | -30.8% | -29.2% | 16.7% | 16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 242.17M | 192.26M | 233.97M | 279.36M |
| Gross Profit | — | — | 105.26M | 125.68M |
| Operating Income | -109,292,714 | -78,091,015 | 42.69M | 60.95M |
| Net Income | -74,512,784 | -53,240,318 | 39.13M | 45.19M |
| Gross Margin | — | — | 45.0% | 45.0% |
| Operating Margin | -45.1% | -40.6% | 18.2% | 21.8% |
| Profit Margin | -30.8% | -29.2% | 16.7% | 16.2% |
| Rev Growth | +26.0% | +26.0% | +1.6% | -9.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 192.5K | 192.5K | 97.71M | 100.55M |
| Total Equity | 213.94M | 213.94M | 421.09M | 435.13M |
| D/E Ratio | 0.00 | 0.00 | 0.23 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -106,518,758 | -80,337,265 | 67.61M | 80.57M |
| Free Cash Flow | — | — | 28.90M | 31.70M |